Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009188 | 0.89 | KMT2A (0.37) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL20009182 | 0.86 | KMT2A (0.39) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL19990908 | 0.75 | KMT2A (0.35) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL22368492 | 0.74 | KMT2A (0.36) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL19990660 | 0.74 | KMT2A (0.36) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL19990663 | 0.74 | KMT2A (0.34) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL19990607 | 0.73 | KMT2A (0.35) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL23927097 | 0.73 | MCL1 (0.35) | KMT2AMEN1ALDH1A1POLBLMNA | |
| SCHEMBL15288393 | 0.72 | KMT2A (0.41) | KMT2AMEN1ALDH1A1PKMFKBP1A | |
| SCHEMBL22368503 | 0.72 | MEN1 (0.36) | KMT2AMEN1ALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | KMT2A 1342/4885MEN1 3698/4885ALDH1A1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.